Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform on July 30th that Shandong Jingxin's Phase 1 project has begun trial production. The purpose of the project implementation is to further improve the company's active pharmaceutical ingredient industry chain and contribute to the cost reduction and efficiency improvement of existing active pharmaceutical ingredient production. The short-term products will mainly supply Shaoxing Jingxin, and the export proportion will gradually increase in the future according to the market situation.
京新药业(002020.SZ)：山东京新的1.1期项目已经开始试生产
Zhejiang Jingxin Pharmaceutical (002020.SZ): Shandong Jingxin's Phase 1 project has started trial production.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.